Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 8/25/14  and contains information from public web pages.

Dr. David G. Hattan

Wrong Dr. David G. Hattan?

Senior Toxicologist CFSAN and FDA...

Phone: (815) ***-****  HQ Phone
U.S. Department of Health and Human Services
200 Independence Avenue, S.W.
Washington D.C. , District of Columbia 20201
United States

Company Description: The U.S. Department of Health and Human Services is the principal federal agency responsible for protecting the health of all Americans and providing essential...   more

Employment History

Board Memberships and Affiliations

  • Member of FAO and WHO Joint Expert Committee On Food Additives


  • Ph.D.
49 Total References
Web References
Dave Hattan, a safety regulator for the FDA, responded that the study only confirmed the need for testing on humans.At independent labs, he insisted, aspartame provoked seizures.
Dangers of Aspartame at dragonfly ranch blog [cached]
"While there were a few inaccuracies (in the original safety tests) there was nothing convincing to keep aspartame off the market," insists David Hattan, Ph.D., acting director of FDA's Division of Health Effects Evaluation.
But, according to the principals of science "if test results cannot be reproduced in a controlled setting then you cannot preclude other factors that might have caused seizure expressions," explains Hattan, who declares he has consumed copious amounts of aspartame with no ill effects.
"Before we allow any substance into the food supply," said Hattan at the FDA, "we have rigorous series of tests that must be performed and they (the proponents of stevia) back off because there is no patent for stevia and it cannot enjoy any commercial exclusivity."
"I am not denying these peoples symptoms," says Hattan at the FDA, "but it is entirely possible that when patients stopped using aspartame they might also coincidentally have had remission of their symptoms."
Return to Subject Index - Main Index, 11 Feb 2006 [cached]
David Hattan, deputy director of the FDA Division of Toxicological Review and Evaluation, concedes that anyone reading the original FDA investigation reports is likely to be "shocked" by what they reveal. He says that the ensuing review of the Searle studies, in which he was involved from the time of his arrival in 1978, was one of the most thorough in the agency's history.
LivingSenior Blog, 29 May 2014 [cached]
The myth actually prompted such a wild fire that Dr. David G. Hattan, Director of the Division of Health Effects Evaluation of the FDA (PDF Warning), was forced to publicly respond. He assured the public that, despite legitimate and multiple attempts to prove otherwise, aspartame does not cause Alzheimer’s disease.
SPI: Public Policy: Food and Drug Packaging Safety - August 1997 Newsletter, 1 Aug 1997 [cached]
Another potential logjam breaker -- through not yet as definitive -- is a new set of statements made by FDA's Director of the Office of Premarket Approval's Division of Health Effects Evaluation, the highly respected Dr. David Hattan.As reported herein, Dr. Hattan has indicated the Agency is now giving high priority to making toxicological significance rulings on substances that are generally unwanted constituents of food-contact materials but that must be adjudged of no public health concern before a petition can be granted.He specifically cited 1,3-butadiene as a priority for evaluation, undoubtedly because at least five pending petitions have been held up for several years for a ruling that this monomer is highly unlikely to become component of food in any noteworthy amount as a result of its use in the manufacture of copolymers made with polybutadiene.
In a recent interview with Food Chemical News, David Hattan, Director of the Office of Premarket Approval's reorganized Division of Health Effects Evaluation (DHEE), stated that reviewing food additive petitions is now the top priority at DHEE.Hattan indicated that action on petitions will take priority over competing projects, such as completion of the Redbook II.In an effort to deal with the petition backlog, DHEE is focusing its attention on substances that are of potential concern in a number of pending petitions.In particular, Hattan identified 1,3-butadiene as a target for priority evaluation.
Other People with the name "Hattan":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.